Following this activity, participants should be able to: (1) Discuss the evidence to support the use of first-line immunotherapy in HCC. (2) Summarize the first- and subsequent-line systemic therapy options for HCC. (3) Describe how the degree of liver dysfunction impacts the decision to treat with systemic therapy versus best supportive care.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
CME included with membership
| Free CME Activity | Free |
| Paid Activity (e.g. Breast/Lung Cancer Congress recordings) | $50 |
| Paid Activity (e.g. Hematologic Malignancies Congress recording) | $90 |
Collected from the provider’s public pages · source
Specialties served/covered
- Addiction Medicine
- Adolescent Medicine
- Anatomic & Clinical Pathology
- Colon & Rectal Surgery
- Communication & Shared Decision-Making
- Dermatopathology
- Evidence-Based Medicine & Research
- Gastroenterology
- Gastrointestinal Surgery
- General Surgery
- Geriatric Medicine
- Gynecologic Oncology
- Head & Neck Surgery
- Health Equity & Inclusion
- Hematology
- Hospice & Palliative Medicine
- Medical Genetics & Genomics
- Medical Leadership & Administration
- Medical Oncology
- Nephrology
- Neurology
- Obstetrics & Gynecology
- Pain Medicine
- Pediatric Hematology-Oncology
- Practice Management & Ethics
- Pulmonary Disease
- Radiation Oncology
- Surgical Oncology
- Thoracic Surgery
- Transplant Hepatology
- Urological Oncology
- Urology
- Cardio-Vascular
- Cross-Specialty
- ENT & Head Neck
- GI & Liver
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Pain & Palliative
- Pathology & Lab
- Primary care
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- On-demand / recorded video
- Credit · Up to 1 credit
- Commercial Support
-
ReleasedJun 1, 2026
-
Last day to claim creditMay 29, 2027 8 months left
-
Answers in CME Inc. (AiCME) Expanding Options, Elevating Outcomes: The Role of First-Line Combination Therapy for Unresectable HCC
-
Learner’s Digest International (TM) Systemic Therapies for Hepatocellular Carcinoma
-
American Association for the Study of Liver Diseases Liver Cancer 100 Series: 102 Immunotherapy in the Management of HCC
-
National Comprehensive Cancer Network Recorded Presentation from Optimizing Patient Outcomes – Small Cell Lung Cancer: Is Immunotherapy Moving the Needle?
-
National Comprehensive Cancer Network Recorded Presentation of NCCN Optimizing Patient Outcomes – Hitting the Right Target: Updates in Biomarker-Directed Therapy for Non-Small Cell Lung Cancer
-
National Comprehensive Cancer Network Recorded Presentation from Optimizing Patient Outcomes: The Changing Treatment Paradigm for Mantle Cell Lymphoma: Improving the Prognosis with Targeted Inhibitors and Evolving Immunotherapy Options
